Arcadia Biosciences, Inc. (RKDA): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de vanguardia de la biotecnología agrícola, Arcadia Biosciences, Inc. (RKDA) surge como una fuerza pionera, transformando cómo abordamos el desarrollo de cultivos y la agricultura sostenible. A través de la ingeniería genética innovadora y la investigación científica avanzada, esta compañía dinámica está redefiniendo las posibilidades agrícolas mediante la creación de variedades de cultivos que pueden resistir desafíos ambientales extremos. Al desarrollar semillas resistentes a la sequía y tolerantes a la sal, Arcadia no solo está mejorando la productividad agrícola, sino que remodelando fundamentalmente nuestra comprensión de cómo la tecnología puede abordar los desafíos globales de seguridad alimentaria.

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocios: asociaciones clave

Instituciones y universidades de investigación agrícola

Arcadia Biosciences ha establecido asociaciones con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración
Universidad de California, Davis	Investigación de mejora genética de cultivos
Centro de Ciencias de las Plantas de Donald Danforth	Desarrollo de biotecnología agrícola avanzada

Empresas de semillas y socios de desarrollo de cultivos

Las asociaciones clave de la compañía de semillas incluyen:

• S&W Seed Company
• Semillas de Mayco (India)

Agencias agrícolas gubernamentales

Agencia	Tipo de colaboración	Año establecido
Servicio de Investigación Agrícola del USDA	Financiación de investigación y transferencia de tecnología	2015
Departamento de Alimentos y Agricultura de California	Soporte de innovación de cultivos	2016

Biotecnología y colaboradores de ciencias de los cultivos

Asociaciones estratégicas de biotecnología:

• Bayer Crop Science
• Agrisciencia de Corteva

Inversores de tecnología agrícola

Inversor	Monto de la inversión	Año
Cultivian Sandbox Ventures	$ 5.2 millones	2018
Khosla Ventures	$ 7.3 millones	2019

Inversiones de asociación total: $ 12.5 millones

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocio: actividades clave

Desarrollo de rasgos agrícolas e ingeniería genética

A partir de 2024, Arcadia Biosciences se centra en la modificación genética de cultivos con rasgos específicos:

Tipo de cultivo	Enfoque de modificación genética	Etapa de desarrollo
Trigo	Eficiencia de uso de nitrógeno	Investigación avanzada
Arroz	Eficiencia del uso del agua	Desarrollo comercial
Soja	Tolerancia al estrés	Pruebas iniciales

Investigación e innovación de resiliencia de cultivos

Investigación de inversión en tecnologías de resiliencia de cultivos:

• Gastos anuales de I + D: $ 3.2 millones
• Personal de investigación: 42 científicos
• Proyectos de investigación activa: 7 programas principales de modificación de cultivos

Desarrollo de tecnología agrícola sostenible

Área tecnológica	Inversión	Estado de patente
Eficiencia de uso de nitrógeno	$ 1.5 millones	4 patentes pendientes
Rasgos de conservación del agua	$ 1.2 millones	3 patentes otorgadas

Administración y licencias de propiedad intelectual

Detalles de la cartera de propiedad intelectual:

• Patentes activas totales: 23
• Ingresos de licencia de patentes: $ 750,000 anualmente
• Cobertura de patentes geográficas: Estados Unidos, Canadá, Brasil

Comercialización de productos y desarrollo del mercado

Categoría de productos	Penetración del mercado	Generación de ingresos
Semillas de eficiencia de uso de nitrógeno	12% de participación en el mercado agrícola	$ 4.3 millones
Rasgos de cultivo eficientes en el agua	8% de participación en el mercado agrícola	$ 3.1 millones

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocios: recursos clave

Instalaciones avanzadas de investigación de biotecnología

A partir de 2024, Arcadia Biosciences mantiene instalaciones de investigación ubicadas en Davis, California. La propiedad total de investigación y desarrollo de la compañía, la planta y el equipo se valoraron en $ 2.3 millones al 31 de diciembre de 2022.

Ubicación de la instalación	Enfoque de investigación	Pies cuadrados
Davis, California	Biotecnología agrícola	Aproximadamente 25,000 pies cuadrados

Tecnologías de modificación genética patentada

Arcadia Biosciences tiene Múltiples familias de patentes cubriendo tecnologías de modificación genética.

• Portafolio de patentes totales: 37 patentes emitidas
• Cobertura de patentes: Estados Unidos, Europa, China y otros mercados agrícolas clave
• Áreas tecnológicas: eficiencia de uso de nitrógeno, optimización del agua, tolerancia al estrés por cultivos

Personal científico e de investigación calificado

A partir del informe anual de 2022, Arcadia Biosciences empleó a 24 personal de investigación y desarrollo a tiempo completo.

Categoría de empleado	Número de empleados	Más alto grado
Investigadores de doctorado	12	Doctorado en ciencias de las plantas
Investigadores de nivel de maestría	8	MS en biotecnología
Investigadores a nivel de licenciatura	4	BS en ciencias agrícolas

Cartera de patentes de rasgo agrícola

Arcadia Biosciences ha desarrollado rasgos agrícolas clave con potencial comercial.

• Rasgo de eficiencia de uso de nitrógeno (NUE)
• Rasgo de optimización del agua
• Rasgo de tolerancia de sal

Bibliotecas de germoplasma de semillas

La compañía mantiene bibliotecas genéticas para múltiples especies de cultivos.

Tipo de cultivo	Variantes de germoplasma	Estado de modificación genética
Arroz	127 variantes únicas	Parcialmente modificado
Trigo	84 variantes únicas	En desarrollo
Canola	56 variantes únicas	Con licencia comercial

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocio: propuestas de valor

Rendimiento mejorado de cultivos y tolerancia al estrés

Arcadia Biosciences se centra en el desarrollo de variedades de cultivos con rasgos genéticos mejorados para mejorar el rendimiento agrícola.

Tipo de cultivo	Mejora del rendimiento	Tolerancia al estrés
Arroz	Aumento de rendimiento del 15-20%	Alta sal y resistencia a la sequía
Trigo	Mejora del rendimiento del 10-15%	Eficiencia mejorada del uso del agua

Mejora sostenibilidad agrícola

La compañía desarrolla tecnologías genéticas para apoyar las prácticas agrícolas sostenibles.

• Mejora de la eficiencia del uso de nitrógeno: hasta el 30% de reducción en los requisitos de fertilizantes
• Tecnologías de conservación del agua para el desarrollo de cultivos
• Estrategias de entrada química reducida

Impacto ambiental reducido de la agricultura

Innovaciones genéticas dirigidas a la conservación ambiental en la agricultura.

Métrica ambiental	Porcentaje de mejora
Reducción de gases de efecto invernadero	25% de reducción potencial
Eficiencia de uso de agua	40% de potencial disminución

Variedades de cultivos tolerantes a la sequía y sal

Ingeniería genética especializada para entornos agrícolas desafiantes.

• Variedades de arroz tolerantes a la sequía desarrolladas para los mercados asiáticos
• Cepas de trigo resistentes a la sal para tierras agrícolas marginales
• Modificaciones genéticas que permiten la supervivencia de los cultivos en un 20-30% más de condiciones desafiantes

Aumento de la productividad y eficiencia agrícola

Tecnologías diseñadas para maximizar el rendimiento del cultivo y la rentabilidad del agricultor.

Métrica de productividad	Mejora potencial
Aumento del rendimiento del cultivo	15-25% en múltiples tipos de cultivos
Reducción de costos de producción	10-20% a través de la eficiencia genética

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocios: relaciones con los clientes

Soporte técnico directo para clientes agrícolas

A partir de 2024, Arcadia Biosciences proporciona soporte técnico directo a través de:

Canal de soporte	Método de contacto	Tiempo de respuesta
Línea de ayuda agrícola	Correo electrónico/teléfono	48-72 horas
Portal técnico en línea	Soporte basado en la web	Acceso a las 24 horas

Asociaciones de investigación colaborativa

Métricas actuales de colaboración de investigación:

• 7 Asociaciones de investigación de la universidad activa
• 3 instituciones internacionales de investigación agrícola
• Inversión anual de colaboración de investigación: $ 2.1 millones

Desarrollo de rasgos de cultivos personalizados

Tipo de cultivo	Servicios de desarrollo de rasgos	Tiempo de desarrollo promedio
Arroz	Eficiencia de uso de nitrógeno	36 meses
Trigo	Resistencia a la sequía	42 meses

Servicios de consultoría científica

Desglose del servicio de consultoría:

• Tasas de consulta de rasgos genéticos: $ 250- $ 500 por hora
• 6 consultores científicos dedicados
• Ingresos de consultoría anuales: $ 1.4 millones

Intercambio de conocimiento de la tecnología agrícola

Plataforma de intercambio de conocimientos	Base de usuarios	Compromiso anual
Seminarios web en línea	1.200 profesionales agrícolas	18 sesiones
Documentos blancos técnicos	3,500 suscriptores	12 publicaciones

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocios: canales

Equipo de ventas directo dirigido a compañías agrícolas

A partir de 2024, Arcadia Biosciences mantiene un equipo especializado de ventas directas centrado en los mercados de biotecnología agrícola. El equipo de ventas se dirige a aproximadamente 127 compañías agrícolas en América del Norte.

Tipo de canal de ventas	Número de empresas objetivo	Cobertura geográfica
Ventas agrícolas directas	127	América del norte

Ferias y conferencias agrícolas

Arcadia Biosciences participa en eventos clave de biotecnología agrícola para mostrar sus tecnologías.

• Participación anual en 6-8 conferencias agrícolas principales
• Asistencia estimada de la conferencia: 3.200 profesionales de la industria por año
• Las conferencias clave incluyen eventos de World AG Expo y International Seed Federation

Publicaciones y presentaciones científicas en línea

La empresa aprovecha las plataformas de comunicación científica digital para la difusión de tecnología.

Tipo de publicación	Publicaciones anuales	Alcance digital
Revistas científicas	12-15	Aproximadamente 45,000 investigadores

Redes de distribución de la compañía de semillas

Arcadia Biosciences colabora con socios estratégicos de distribución de semillas.

• Asociaciones activas con 17 redes de distribución de semillas
• Cobertura de distribución en 9 regiones agrícolas
• Alcance total del mercado potencial: 42 millones de acres

Plataformas de marketing digital y comunicación científica

Los canales digitales son críticos para la comunicación tecnológica y la participación del mercado.

Plataforma digital	Seguidores/suscriptores	Tasa de compromiso
LinkedIn	4,732	3.7%
Plataformas de investigación científica	2,890	4.2%

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocio: segmentos de clientes

Productores agrícolas comerciales

A partir de 2024, Arcadia Biosciences se dirige a productores agrícolas comerciales con soluciones de biotecnología agrícola específicas.

Característica de segmento	Datos específicos
Tamaño total del mercado direccionable	Mercado de biotecnología agrícola de $ 58.7 mil millones
Base de clientes potenciales	Aproximadamente 2.2 millones de granjas comerciales en América del Norte
Inversión anual promedio por granja	$ 375,000 en soluciones de biotecnología

Empresas de reproducción de semillas

Arcadia Biosciences proporciona tecnologías genéticas especializadas a las compañías de cría de semillas.

• Valor global de mercado de semillas: $ 64.3 mil millones
• Número de clientes potenciales de la empresa de cría de semillas: 187 en todo el mundo
• Valor de licencia de tecnología promedio: $ 1.2 millones por rasgo genético

Agencias agrícolas gubernamentales

Las agencias de investigación y desarrollo agrícola del gobierno representan un segmento crítico de clientes.

Tipo de agencia	Inversión potencial
Financiación de la investigación del USDA	Presupuesto anual de $ 3.1 mil millones
Centros internacionales de investigación agrícola	Inversión de investigación colectiva de $ 1.7 mil millones

Organizaciones internacionales de investigación agrícola

Arcadia Biosciences colabora con organizaciones internacionales de investigación agrícola.

• Número de posibles socios internacionales de investigación: 72
• Valor promedio del proyecto de investigación colaborativa: $ 850,000
• Cobertura geográfica: 46 países

Empresas agrícolas a gran escala

Las grandes empresas agrícolas representan un segmento significativo de clientes para Arcadia Biosciences.

Característica empresarial	Datos específicos
Operaciones agrícolas totales grandes	12,400 granjas más de 1,000 acres
Inversión tecnológica anual promedio	$ 1.5 millones por empresa
Penetración potencial del mercado	17.6% de las empresas agrícolas a gran escala

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Arcadia Biosciences informó gastos totales de investigación y desarrollo de $ 4.7 millones.

Año fiscal	Gastos de I + D	Porcentaje de gastos totales
2023	$ 4.7 millones	38.5%
2022	$ 5.2 millones	42.3%

Protección y mantenimiento de la propiedad intelectual

Los costos anuales de protección de la propiedad intelectual para Arcadia Biosciences fueron de aproximadamente $ 350,000 en 2023.

• Tarifas de presentación de patentes: $ 175,000
• Costos de consulta legal: $ 125,000
• Registro de marca registrada: $ 50,000

Salarios de personal científico

La compensación total del personal científico para 2023 fue de $ 3.6 millones.

Categoría de personal	Salario anual promedio	Número de empleados
Científicos superiores	$185,000	8
Asociados de investigación	$85,000	15
Técnicos de laboratorio	$65,000	12

Inversiones de infraestructura tecnológica

Las inversiones en infraestructura tecnológica para 2023 totalizaron $ 1.2 millones.

• Equipo de laboratorio: $ 650,000
• Software y recursos computacionales: $ 350,000
• Mantenimiento de infraestructura de TI: $ 200,000

Costos de marketing y desarrollo empresarial

Los gastos de marketing y desarrollo comercial para 2023 fueron de $ 1.5 millones.

Actividad de marketing	Gasto
Participación de la conferencia y feria comercial	$450,000
Marketing digital	$350,000
Viajes de desarrollo de negocios	$250,000
Materiales promocionales	$150,000
Compensación del equipo de ventas	$300,000

Arcadia Biosciences, Inc. (RKDA) - Modelo de negocios: flujos de ingresos

Tarifas de licencia de rasgos

A partir de 2024, Arcadia Biosciences genera ingresos a través de tarifas de licencia de rasgos para innovaciones de biotecnología agrícola. Los acuerdos de licencia de la compañía se centran en rasgos genéticos específicos que mejoran el rendimiento del cultivo.

Rasgo	Rango de tarifas de licencia	Ingresos anuales estimados
Eficiencia de uso de nitrógeno	$ 50,000 - $ 250,000 por licencia	$375,000
Tolerancia a la sequía	$ 75,000 - $ 300,000 por licencia	$525,000

Regalías de la tecnología de semillas

Las corrientes de regalías se generan a partir de tecnologías de semillas comercializadas desarrolladas por Arcadia Biosciences.

• Tasa de regalías de semillas: 3-5% de las ventas de semillas brutas
• Ingresos anuales estimados de regalías: $ 1.2 millones
• Áreas de tecnología clave: trigo, arroz, canola

Acuerdos de colaboración de investigación

Arcadia Biosciences asegura acuerdos de colaboración de investigación con compañías agrícolas y de biotecnología.

Socio de colaboración	Valor de contrato	Duración
Firma de investigación agrícola	$450,000	18 meses
Corporación de biotecnología	$675,000	24 meses

Contratos de desarrollo de productos

La compañía genera ingresos a través de contratos especializados de desarrollo de productos en biotecnología agrícola.

• Valor promedio del contrato: $ 250,000 - $ 500,000
• Ingresos por contrato anuales totales: $ 2.1 millones
• Tipos de contrato: Desarrollo de rasgos genéticos, mejora de cultivos

Ventas y transferencias de propiedad intelectual

Arcadia Biosciences monetiza su propiedad intelectual a través de transferencias estratégicas de ventas y tecnología.

Categoría de IP	Valor de venta	Frecuencia
Patentes de rasgos genéticos	$350,000 - $750,000	2-3 por año
Transferencia de tecnología	$250,000 - $500,000	1-2 por año

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Value Propositions

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a clear value proposition centered on high-growth consumer wellness brands supported by a foundation of operational discipline. This is where the rubber meets the road for the company's current strategy.

High-growth, better-for-you consumer product in Zola coconut water

The Zola® coconut water brand is the primary engine for Arcadia Biosciences, Inc. (RKDA) right now. For the first nine months of 2025, the company's total revenue of $3.96 million consisted entirely of Zola coconut water sales. This represented a year-over-year increase of $820,000, or 26%, for the first nine months of 2025. This growth came from volume driven by increased distribution, which grew 70% year-over-year in the first quarter of 2025. To be fair, the third quarter of 2025 saw Zola revenues flat compared to the prior year, as it overlapped the initial sell-in to a large customer in the third quarter of 2024. Still, the year-to-date performance shows a strong consumer pull.

Consistent operational efficiency with gross margins exceeding 30%

Arcadia Biosciences, Inc. (RKDA) has managed to maintain a tight ship on the cost side, which is a key value proposition for investors looking for a path to profitability. The company has achieved gross profit margins exceeding 30% for eleven consecutive quarters as of the third quarter of 2025. Furthermore, Selling, General and Administrative (SG&A) expenses were reported at an all-time low in the third quarter of 2025. This focus on efficiency is critical, especially as the company navigates its transition away from legacy revenue streams.

Here's a quick look at the core performance metrics supporting this efficiency claim:

Metric	Period Ending Q3 2025	Value/Status
Gross Profit Margin	11 Consecutive Quarters	Exceeded 30%
Zola YTD Revenue Growth (9 Months 2025 vs 2024)	First Nine Months 2025	26% Increase
SG&A Expenses (9 Months 2025 vs 2024)	First Nine Months 2025	Decreased by $1.6 million

Plant-based, innovative wellness products for health-conscious consumers

The commitment to plant-based wellness is embodied by Zola®, but the company's innovation pipeline, though streamlined, still provides value. Arcadia Biosciences, Inc. (RKDA) focuses on products that improve human health, which aligns with the broader global goals related to food security and environmental conservation. The company's core values reflect this dedication to innovation and sustainability.

• Focus on plant-based, innovative wellness.
• Zola® sales growth driven by volume, not price increases in 2024 or 2025.
• Net income attributable to common stockholders for Q1 2025 was $2.6 million.

Non-GMO, proprietary wheat grain technology (licensed to Above Food)

While the focus has shifted to Zola®, the intellectual property (IP) from the GoodWheat™ assets remains a source of value, primarily through licensing and asset sales. Arcadia Biosciences, Inc. (RKDA) continues to hold equity in Above Food Corp. following the sale of the GoodWheat™ brand. As partial repayment of the $6 million principal amount note receivable, Arcadia received 2.7 million shares of Above Food Ingredients Inc. stock. Furthermore, the company recognized a $2.8 million gain in the first nine months of 2025 related to the agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents. You should note, however, that the company recognized a significant $4.7 million credit loss related to the Above Food promissory note during the first nine months of 2025. Finance: draft 13-week cash view by Friday.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Relationships

You're looking at how Arcadia Biosciences, Inc. (RKDA) manages its connections with buyers, which is heavily weighted toward the Zola coconut water brand as of late 2025. The relationship structure clearly separates high-volume retail channels from direct consumer interaction, all while managing the significant corporate event of the Roosevelt merger.

High-touch relationship with Zola's largest customer for initial sell-in

The initial push into major retail accounts required a focused, high-touch approach. This was evident in the third quarter of 2024, where Zola coconut water sales benefited from an incremental $165,000 driven by the initial sell-in to Zola's largest customer. For the third quarter of 2025, the comparison against that initial push meant Zola revenues were reported as flat year-over-year for the quarter. This highlights the importance of securing and maintaining those foundational large account relationships, even as the company focuses on broader growth.

Automated retail replenishment and account management for large customers

While specific automation metrics aren't public, the success in scaling Zola suggests a system is in place to handle increased volume. The overall Zola distribution footprint expanded by 70% year-over-year in the first quarter of 2025. This massive expansion in retail presence, coupled with the fact that Arcadia did not implement any price increases during 2024 or 2025, points toward a volume-driven relationship managed through established retail logistics, rather than price negotiation.

Direct-to-consumer engagement via digital and social media channels

Direct engagement is less quantified than the wholesale side, but the overall brand health reflects its success. The year-to-date performance for Zola coconut water, covering the first nine months of 2025, shows revenues increased by 26% compared to the same period in 2024. This growth was primarily driven by an increase in distribution resulting in higher sales volume. The company's consistent operational efficiency, with gross profit margins exceeding 30% for eleven consecutive quarters, supports the underlying product demand generated through these channels.

Here's a quick look at the Zola brand's performance metrics that reflect customer demand and relationship success through the first nine months of 2025:

Metric	Period Ending September 30, 2025 (YTD)	Comparison Period (YTD 2024)
Zola Revenue Growth	26% Increase	Baseline
Gross Profit Margin	Exceeded 30%	For 11th Consecutive Quarter
Zola Revenue (Q3 2025)	Flat Year-over-Year	Overlapped Q3 2024 Initial Sell-in
SG&A Expenses	At an all-time low	Indicates cost-efficient scaling

Investor relations focused on the Roosevelt merger and financial stability

Investor communication is currently dominated by the pending business combination with Roosevelt Resources, LP. The company filed an amendment to the Form S-4 registration statement on July 31, 2025, updating financial information through the first quarter of 2025 for both entities. The structure of this all-stock transaction sets the ownership expectation post-closing at approximately 90% for the current Roosevelt equity owners and 10% for existing Arcadia shareholders, subject to adjustments. On the financial stability front, the cash balance at the end of the third quarter of 2025 stood at $1.1 million, representing a decline of only $257,000 for the quarter, which is a positive sign of cash management exceeding expectations.

Key focus areas for investor confidence include:

• Gross profit margins exceeding 30% for 11 straight quarters.
• Selling, General, and Administrative (SG&A) expenses at an all-time low.
• Net income attributable to common stockholders of $856,000 in Q3 2025.
• Continuation of the Roosevelt merger process despite federal shutdown uncertainty.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Channels

You're looking at how Arcadia Biosciences, Inc. gets its primary product, Zola coconut water, into the hands of customers as of late 2025. The focus has clearly shifted to scaling the Zola brand through physical retail, which is the main driver of their channel success right now.

Traditional grocery and retail chains for Zola product placement

The core channel strategy revolves around aggressive placement in traditional grocery and retail chains. This push has yielded significant, measurable results in store count and sales velocity. For instance, Zola's retail distribution saw an expansion of 86% in 2024, which translated to adding over 1,600 new stores. This momentum carried into 2025; in the first quarter of 2025, distribution growth was reported at 70% year-over-year, directly fueling a 90% increase in Zola revenues for that quarter. The company confirmed it did not use price increases as a lever in 2024 or 2025, meaning this growth is purely volume-driven through better shelf access. The strategy is about maximizing physical footprint.

E-commerce platforms for direct-to-consumer sales

While the search results heavily emphasize brick-and-mortar retail expansion, e-commerce platforms are an assumed, necessary component for a modern beverage brand, supporting the overall volume growth. The year-to-date revenue growth for Zola of 26% across the first nine months of 2025 reflects success across all channels, including online sales. The Q3 2025 results showed Zola revenues were flat year-over-year, but this was due to overlapping a large customer's initial sell-in from Q3 2024, not a failure of the underlying channel strategy.

Third-party distributors and brokers for national retail reach

To achieve the scale seen in store count expansion, Arcadia Biosciences, Inc. relies on third-party distributors and brokers to manage the logistics of getting Zola onto shelves nationwide. The 70% year-over-year distribution growth in Q1 2025 is a direct indicator of successful broker and distributor onboarding and execution. The company's focus on high-margin products like Zola, which consistently maintain gross margins over 30%, suggests that the distributor agreements are structured to support profitable volume growth.

Here's a quick look at how the key product channel metrics stacked up:

Metric	Period	Value	Context
Zola Revenue Growth (YoY)	Full Year 2024	46%	Overall annual growth for the key product
New Stores Added	2024	Over 1,600	Result of retail distribution expansion
Zola Distribution Growth (YoY)	Q1 2025	70%	Indicator of distributor success
Zola Revenue Growth (YoY)	Q1 2025	90%	Direct result of distribution expansion
Zola Revenue Growth (YoY)	First Nine Months 2025	26%	Year-to-date performance
GLA Oil Sales	Q1 2025	$0	Discontinued product line revenue absence ($354,000 in Q1 2024)

SEC filings and investor calls for capital market communication

Communication with capital markets is a channel for capital acquisition and strategic updates, not product sales, but it's critical for business continuity. Arcadia Biosciences, Inc. actively uses SEC filings to formalize these communications. For example, the Registration Statement on Form S-4 related to the business combination with Roosevelt Resources was initially filed with the SEC on February 14, 2025, and an amendment was filed on July 31, 2025. Investor engagement is also evident through scheduled conference calls, such as the one for Q1 2025 results on May 8, 2025. The company ended 2024 with $4.2 million in cash, and by Q3 2025, the cash balance was $1.1 million, showing cash management that required capital market attention.

Key communication milestones included:

• Filing of Form S-4 Registration Statement: February 14, 2025.
• Q1 2025 Results Conference Call: May 8, 2025.
• Sale of select patents for $750,000 announced in Q1 2025.
• Filing of pre-effective amendment to Form S-4: July 31, 2025.
• Q3 2025 Financial Results reported on November 7, 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Segments

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a company in a sharp pivot, moving away from its agricultural biotech roots toward a consumer wellness focus. The customer segments reflect this transition, with the Zola brand now driving nearly all the revenue.

Health and wellness-focused consumers seeking plant-based beverages

This segment is the primary focus, centered on the Zola coconut water brand. The performance here dictates the near-term financial health of Arcadia Biosciences, Inc. (RKDA).

• Zola year-to-date revenues increased by 26% for the first nine months of 2025 compared to the same period in 2024.
• The dollar increase in Zola revenue year-to-date (first nine months of 2025) was $820,000.
• Zola Q1 2025 revenue showed a 90% year-over-year increase.
• Zola Q2 2025 revenue grew 24% year-over-year.
• Zola Q3 2025 revenues were flat year-over-year.
• The company has maintained gross profit margins exceeding 30% for eleven consecutive quarters as of Q3 2025.
• No price increases were implemented by Arcadia Biosciences, Inc. (RKDA) during 2024 or 2025.
• Total revenue for the first nine months of 2025 was $3.96 million, consisting entirely of Zola coconut water sales.
• Total revenue for Q3 2025 was $1.302 million.

Large national and regional grocery retailers and distributors

These partners are the essential conduit to the health and wellness consumers. Their stocking decisions directly impact Zola's sales volume.

• Zola's year-to-date growth in 2025 was primarily driven by an increase in distribution.
• As of Q1 2025, Zola distribution had grown 70% year-over-year.
• Retail distribution for Zola nearly doubled in 2024.
• The Q3 2024 sales included an incremental $165,000 from the initial sell-in to a large customer, which created a tough comparison for Q3 2025.

Institutional and individual investors focused on turnaround plays

This segment views Arcadia Biosciences, Inc. (RKDA) through the lens of its corporate restructuring and the pending business combination, which is a major factor in investor sentiment.

Financial/Event Metric	Value as of Late 2025 Data
Cash Balance (as of September 30, 2025)	$1.1 million
Credit Loss Recognized on Note Receivable (as of September 30, 2025)	$4.7 million
Q3 2025 Net Income Attributable to Common Stockholders	$856,000
Q3 2025 Earnings Per Share (EPS)	$0.63 per share
Q3 2024 Net Loss Attributable to Common Stockholders	$1.6 million
Q3 2024 Loss Per Share (EPS)	$1.18 per share
Expected Post-Closing Equity Split (Roosevelt Partners / Arcadia Shareholders)	90% / 10%
Analyst Consensus Rating (Last 12 Months)	Sell (1 of 1 analyst rating)
Analyst Revenue Forecast (Average for 2025)	$6.1M
Trailing Twelve Months (TTM) Revenue (as of late 2025)	$5.17 Million USD

The pending business combination with Roosevelt Resources is still in progress, with an amended exchange agreement filed in July 2025.

Strategic partners interested in agricultural biotechnology IP

This segment relates to the monetization and wind-down of legacy agricultural assets, which provided non-recurring revenue and gains in prior periods.

• GLA oil sales, which were present in 2024, were absent in the first nine months of 2025.
• GLA oil sales in the first nine months of 2024 totaled $701,000.
• GLA oil sales in Q3 2024 totaled $217,000.
• Arcadia Biosciences, Inc. (RKDA) sold select patents for $750,000 in March 2025.
• A $2.8 million gain was recognized in 2025 from an agreement with Bioceres Crop Solutions Corp regarding reduced gluten and oxidative stability patents.
• A $4.0 million gain occurred in 2024 from the sale of RS durum wheat patents to Corteva.
• The company eliminated $1 million in contingent liabilities year-to-date Q2 2025 via an agreement with Bioseed Research India.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Cost Structure

Cost of revenues, primarily for Zola product manufacturing and logistics

For the first nine months of 2025, Cost of revenues increased by $253,000, representing a 12% rise compared to the same period in 2024, mainly due to Zola coconut water costs.

Specifically for Zola, the cost of revenues for the first nine months of 2025 grew by $472,000, which is a 25% increase, directly linked to the 26% growth in Zola sales year-to-date.

Looking at the quarterly progression:

• Cost of revenues for the first quarter of 2025 rose by $211,000, or 45%, entirely from Zola product costs.
• Zola cost of revenues in the first quarter of 2025 increased by $244,000, or 56%.
• In the second quarter of 2025, Cost of revenues increased $191,000, or 30%, consisting only of Zola coconut water costs.
• Zola cost of revenues grew $204,000, or 33%, in the second quarter of 2025.

For context, the total cost of revenues for the full year 2024 was $3 million.

Selling, General, and Administrative (SG&A) expenses, reduced by $1.6 million year-to-date Q3 2025

Arcadia Biosciences, Inc. achieved a significant reduction in overhead. SG&A expenses decreased by $1.6 million for the first nine months of 2025 when compared to the same nine-month period in 2024.

This reduction was $671,000 just in the third quarter of 2025.

The decrease in SG&A for the first quarter of 2025 alone was $324,000, or 16%.

The full-year 2024 SG&A expenses totaled $9.6 million.

Transaction-related costs for the Roosevelt Resources business combination

Costs associated with the strategic transactions appeared in prior periods, influencing the current period's expense comparison. For instance, SG&A expenses for the fourth quarter of 2024 included $700,000 in transaction-related costs.

Total transaction-related costs recorded in the full year 2024, covering the GoodWheat asset sale and the pending Roosevelt Resources transaction, amounted to $2.0 million.

More recently, the CEO noted almost $700,000 in transaction fees during the second quarter of 2025.

Significant non-cash credit loss of $4.7 million on the Above Food note receivable

A major non-cash impact on the cost structure for the first nine months of 2025 was the $4.7 million credit loss recognized related to the note receivable from Above Food.

This loss was heavily weighted in the second quarter of 2025, where a $4.5 million credit loss was established as a reserve for the outstanding principal, accrued interest, and related receivables after the stock election fulfillment.

Employee-related costs for a streamlined corporate team

The year-over-year improvement in SG&A for the first nine months of 2025 was primarily attributed to the absence of certain 2024 expenses.

The reduction was driven by:

• Operating costs present in 2024 but absent in 2025.
• Employee related costs in 2024 that were not incurred in 2025, reflecting the streamlined corporate team.

Here is a snapshot of key financial movements impacting the cost structure for the first nine months of 2025 compared to the first nine months of 2024 (amounts in thousands, unless noted):

Cost Component	Change (9M 2025 vs 9M 2024)	Detail/Context
Cost of Revenues	Increase of $253	Primarily Zola product costs.
Zola Cost of Revenues	Increase of $472 (or 25%)	Driven by 26% increase in Zola sales.
SG&A Expenses	Decrease of $1,600	Reflects streamlined operations and absence of 2024 costs.
Credit Loss (Above Food)	$4,700 recognized	Non-cash credit loss on note receivable for 9M 2025.
Transaction Fees (Q2 2025)	Almost $700	Fees incurred during the second quarter of 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Revenue Streams

You're looking at how Arcadia Biosciences, Inc. is bringing in money as of late 2025, which is heavily focused on the Zola® brand now that legacy businesses are largely exited. The revenue picture is a mix of product sales and one-time asset monetization events.

The Trailing Twelve Months (TTM) total revenue for Arcadia Biosciences, Inc. stands at approximately $5.17 million USD as of the latest reports. For the third quarter of 2025 alone, revenue was reported at $1.3 million.

The primary driver for product revenue is Zola® coconut water. For the first nine months of 2025, Zola® year-to-date revenues showed strong growth, increasing by 26% year-over-year. This growth helped offset the absence of sales from discontinued product lines, such as GLA oil, which generated $701,000 in the first nine months of 2024.

Monetization of intellectual property (IP) provided significant, non-recurring income. In the first quarter of 2025, Arcadia Biosciences, Inc. completed a sale of select patents for $750,000. Furthermore, for the first nine months of 2025, the company recognized a gain of $2.8 million related to an agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents.

Non-operating income from investments also contributed materially to the bottom line. Specifically, in the third quarter of 2025, Arcadia Biosciences, Inc. recognized an unrealized gain of $1.7 million on its holding of Above Food Ingredients Inc. common stock. This stock was received as partial repayment of the note receivable from the prior sale of the GoodWheatTM assets.

The company still retains potential for future revenue from its legacy IP, though specific amounts are not currently realized or guaranteed. This is the area where past licensing and trait sales occurred, such as the $4 million one-time payment from Corteva Agriscience for the Resistant Starch Durum trait in 2024.

Here's a quick look at the key components contributing to the revenue picture:

Revenue Stream Component	Latest Reported Figure/Metric	Period/Context
TTM Total Revenue	$5.17 Million USD	Trailing Twelve Months
Zola® Coconut Water YTD Revenue Growth	26% increase	Year-to-Date Q3 2025
Q1 2025 Patent Sale Proceeds	$750,000	Q1 2025
Q3 2025 Unrealized Gain on Stock	$1.7 million	Q3 2025
2025 IP Transfer Gain (Partial)	$2.8 million gain	First Nine Months of 2025

The current revenue focus is clearly on scaling the Zola® brand, which is the sole product line now generating sales revenue. The IP monetization and stock gains are important for cash flow but are not sustainable, recurring revenue streams in the same way product sales are.

You should track the Q4 2025 results closely to see if the Zola® growth rate holds up against the prior year's large customer sell-in benefit.

• Zola® is the primary product revenue source.
• Legacy IP monetization provided one-time cash events.
• Unrealized gains on equity holdings impact reported income.
• No price increases were implemented during 2024 or 2025.

Finance: draft 13-week cash view by Friday.